Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Profiling and Oral Chemotherapy for Breast Cancer in Uganda
NCT03518242Phase 1Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2018
- Primary completion
- May 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide, methotrexate and capecitabine in breast cancer, sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Distribution of molecular subtypes at 9 months, Sensitivity to polymerase chain reaction (PCR) at 9 months and 4 more. Started Jun 2018; status: completed.
02
Drugs
cyclophosphamidemethotrexatecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03518242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03518242.